Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study

• Status: Withdrawn
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this observational study is to compare the use of an extended release paracetamol formulation with standard paracetamol in a cohort of Australian concessional patients with osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

• Participants prescribed with a paracetamol product and categorized as a concessional patient

• Participants with new episodes of OA (no history of OA paracetamol in previous 12 months) or suffering from chronic OA (history of OA paracetamol in the previous 12 months)

Exclusion Criteria:

• Participants with Rheumatoid arthritis or other auto-immune inflammatory conditions

• Participants receiving the following anti-rheumatoid therapies:Immunimodulators such as methotrexate, leflunamide and TNF blockers

• Participants receiving treatment for cancer pain